Shares of Syros Pharmaceuticals (NASDAQ:SYRS) have earned an average recommendation of “Buy” from the eleven research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $21.13.
Several brokerages have issued reports on SYRS. BidaskClub raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 22nd. HC Wainwright reissued a “hold” rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday, March 14th. Oppenheimer reissued a “buy” rating and issued a $28.00 price objective on shares of Syros Pharmaceuticals in a research note on Thursday, December 7th. Zacks Investment Research raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Friday, January 5th. Finally, Wedbush reissued an “outperform” rating and issued a $13.00 price objective (up previously from $11.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, March 13th.
In other news, Director Srinivas Akkaraju acquired 209,424 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was acquired at an average price of $9.55 per share, with a total value of $1,999,999.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 33.60% of the stock is owned by company insiders.
Shares of NASDAQ:SYRS traded up $0.36 during trading on Friday, reaching $12.98. The company’s stock had a trading volume of 119,043 shares, compared to its average volume of 198,334. Syros Pharmaceuticals has a 12 month low of $6.30 and a 12 month high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings results on Monday, March 12th. The company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.01). sell-side analysts forecast that Syros Pharmaceuticals will post -2.22 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This article was originally published by WKRB News and is the property of of WKRB News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.wkrb13.com/2018/04/01/analysts-set-syros-pharmaceuticals-syrs-pt-at-21-13.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.